secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2026-06-22T20:43:01+00:00
Accession:  0001689548-26-000066
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Breakthrough Therapy Designation for Praxis Precision Medicines' elsunersen for SCN2A-DEE
--------------------------------------------------------------------------------

- FDA granted Breakthrough Therapy Designation for elsunersen (PRAX-222), an antisense oligonucleotide for seizures in SCN2A Developmental and Epileptic Encephalopathy.
- BTD expedites development and regulatory review; supported by positive topline data from EMBRAVE Part A trial.
- EMBRAVE Part A was a randomized, sham-controlled Phase 1/2 study in nine pediatric patients aged 2–12 years with early-seizure-onset SCN2A-DEE.
- The designation covers Gain of Function variants in SCN2A.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000066/0001689548-26-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000066/prax-20260622.htm
  HTML page:      https://secwatch.observer/filing/0001689548-26-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer